Dr Steineger (51) is Head of Strategic Innovation management in Nutrition & Health at BASF. She has served as Vice President Business Development and Vice President Investor Relations and Communications at Pronova BioPharma (now part of BASF). Prior to this, she was Senior Associate with Neomed management, an international investment firm focusing on the healthcare and life science industry. Dr Steineger has also background as an independent adviser focusing on start-ups in the Life Science/ Health Care sector and as an equity analyst at Kreditkassen (now part of Nordea Markets) based in Oslo and Copenhagen. She began her professional career at Nycomed Pharma, where she worked in the area of clinical research and international marketing. Current board positions include Strongbridge BioPharma Plc and PCI Biotech ASA. She holds a BSc and a PhD in Medical Biochemistry from the University of Oslo. She has served as a director in the company since November 2014. Dr Steineger is a Norwegian citizen and resides in Norway. She is an independent director of the board. Dr Steineger attended 18 board meetings in 2016.

Business Development ,Investor Relations,healthcare ,clinical research and international marketing